Results 201 to 210 of about 1,728,519 (315)

Evaluating a Mendelian Risk Prediction Model That Aggregates Across Genes and Cancers. [PDF]

Genet Epidemiol
Liang JW, Idos GE, Hong C, Shannon KM, Bear LM, Pichardo JM, Guan Z, McCarthy AM, Ford JM, Kurian AW, Gruber SB, Braun D, Parmigiani G.   +12 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation

Cancer Management and Research
Shibo Gao,* Yukun Liu,* Jinglin Kong, Linkuan Huangfu, Yuchuan Yang, Haiyang Cui, Xiaocong Sun, Shuling Shi, Daoke Yang Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic ...
Gao S, Liu Y, Kong J, Huangfu L, Yang Y, Cui H, Sun X, Shi S, Yang D   +8 more
doaj  

Development and external validation of a novel prediction model for the TraumaTriage App. [PDF]

Eur J Trauma Emerg Surg
Gulickx M, Lokerman RD, van der Sluijs R, Tuinema RM, van Vliet R, Hietbrink F, Groenwold RHH, van Heijl M.   +7 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Development of a Prognosis Prediction Model for Pediatric Sepsis Based on the NLPR

Huabin Wang,1– 4 Rui Zhang,1,3,4 Jing Xu,1,3,4 Min Zhang,1,3,4 Xueyun Ren,1,3,4 Yuhui Wu5 1Department of Pediatrics, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, People’s Republic of China; 2Postdoctoral Mobile ...
Ren X, Zhang M, Wang H, Zhang R, Xu J, Wu Y   +5 more
core  

Establishment of a prediction model for malignant probability of pulmonary nodules in an adenocarcinoma-predominant cohort. [PDF]

PeerJ
Li F, Yu X, Xu K, Zhang G.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Development and validation of a MODS risk prediction model for organophosphorus poisoning patients. [PDF]

Front Med (Lausanne)
Yu H, Wang K, Wu H, Li F.
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source